cyc 202 has been researched along with triphenyltetrazolium in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (triphenyltetrazolium) | Trials (triphenyltetrazolium) | Recent Studies (post-2010) (triphenyltetrazolium) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 707 | 1 | 115 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Dong, Q; Lü, J; Luo, X; Pan, D; Wang, W; Xie, M; Yu, Z; Zhang, Q | 1 |
1 other study(ies) available for cyc 202 and triphenyltetrazolium
| Article | Year |
|---|---|
Cell cycle inhibition attenuates microglial proliferation and production of IL-1beta, MIP-1alpha, and NO after focal cerebral ischemia in the rat.
Topics: Animals; Aquaporins; Brain Ischemia; Cell Count; Cell Cycle; Cell Line, Transformed; Cell Proliferation; Disease Models, Animal; Eye Proteins; In Situ Nick-End Labeling; Injections, Intraventricular; Interleukin-1beta; Male; Mice; Microglia; Neurologic Examination; Nitric Oxide; Protein Kinase Inhibitors; Purines; Rats; Rats, Sprague-Dawley; Roscovitine; Tetrazolium Salts; Up-Regulation | 2009 |